Genentech Provides Update On Avastin For Advanced Breast Cancer
Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for AvastinĀ® (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment...
More... |
All times are GMT -7. The time now is 04:29 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021